
S&P Global, CME Group Exit OSTTRA with $3.1B Sale to KKR
S&P Global and CME Group have sold their joint venture, OSTTRA, to KKR for $3.1 billion, with proceeds split equally under their 50/50 ownership.
Formed in 2021, OSTTRA delivers post-trade solutions for the global OTC market, covering interest rates, FX, credit, and equity asset classes. Co-CEOs Guy Rowcliffe and John Stewart will continue leading the management team.
KKR aims to introduce a broad-based equity ownership program for OSTTRA’s 1,500 employees and prioritize investments in technology and innovation. The deal is set to close in the second half of 2025.
“OSTTRA has generated significant growth over the past several years, and we are pleased with the role our joint venture played in driving the company forward,” said CME Group Chairman and CEO Terry Duffy. “Looking ahead, as the post-trade marketplace continues to evolve, we are confident that KKR will further scale this business and extend the important efficiencies that OSTTRA delivers to clients.”
Barclays and Davis Polk served as financial and legal advisors, respectively, to S&P Global. Citi and Skadden served as financial and legal advisors, respectively, to CME Group. Goldman Sachs & Co. LLC and BofA Securities, and Simpson Thacher & Bartlett served as financial and legal advisors, respectively, to KKR.